Glycomics Market Size, Share & Industry Analysis By Product (Reagents & Consumables, Enzymes, Kits, Instruments, and Services & Software), By Application (Drug Discovery & Development, Diagnostic and Biomarker Discovery, and Others), By End User (Pharmaceutical & Biotechnological Companies, Academic and Research Institutes, CROs & CDMOs, and Others), and Regional Forecast, 2026-2034

The global glycomics market size was valued at USD 1.4 billion in 2024 and is projected to reach USD 4.0 billion by 2032, exhibiting a CAGR of 14.0% during the forecast period. The glycomics market comprises various components and services used to analyze glycans and glycosylation patterns in biological systems. The market utilizes advanced analytics and reagent kits to analyze the complex glycosylation process, supporting pharmaceutical research. Glycans influence numerous biological processes, from immunity to cancer. They have a wide range of applications in drug discovery and development. They are used to design and optimize monoclonal antibodies, vaccines, and other complex therapeutics by fine-tuning their glycosylation for better efficacy and safety.

Moreover, strategic collaborations, new product launches, and mergers and acquisitions by major players in the market offer significant growth opportunities, underscoring their importance.  

• For instance, in June 2025, GlycoNet, Canada’s national network advancing glycomics research and innovation, which focuses on glycomics research, collaborated with Japan’s Institute for Glyco-core Research (iGCORE) to accelerate advancements in health, biotechnology, and sustainable agriculture.

Glycomics Market Driver

Surging Adoption of Biologics and Biosimilars to Fuel the Market Growth

One of the key factors driving market growth is the increasing adoption of biosimilars and biologics. Glycomics play a critical role in their production and possess crucial attributes that impact the efficacy, safety, and half-life of monoclonal antibodies, fusion proteins, and other advanced therapeutics. These glycan workflows are used to validate the safety of the product after it has been produced. Thus, regulatory agencies are increasingly pushing pharma and biotech companies to invest in robust glycan analysis workflows and compliant instrumentation. Additionally, the rising global burden of cancer, autoimmune, metabolic, and infectious diseases is accelerating research into glycan-based biomarkers and targeted therapies, expanding the use of glycomics. Such factors are expected to drive the market's growth.

• For instance, in January 2024, Vector Laboratories, a pioneer in innovative proteomic and glycomic research solutions, collaborated with Navinci Diagnostics, a leader in innovative in situ proximity ligation assay-based solutions. This collaboration aimed to develop cutting-edge biomarker discovery tools, allowing the detection of specific protein glycosylation in tissue samples for the first time.

To know how our report can help streamline your business, Speak to Analyst

In February 2024, Journal of Biological Chemistry published a study titled ‘GlyComb: A Novel Glycoconjugate Data Repository that Bridges Glycomics and Proteomics’. The study reported the breakdown of glycopeptide and glycoprotein entries registered in GlyComb as of August 31, 2023. There are 99,240 glycopeptide entries registered in GlyComb in total, of which (A) 59% (58,682 entries) contain only N-linked glycosylation and 41% (40,203 entries) contain only O-linked glycosylation.

Glycomics Market Restraint

Technical Complexity of Glycomics Workflow to Increase Cost and Hamper Market Growth

A key restraint for the glycomics market is the high cost and technical complexity of required tools and workflows. They utilize advanced mass spectrometers, UHPLC systems, and specialized glycan kits and enzymes, resulting in a significant investment. The specialized kits and enzymes used in these workflows are of high grade and often priced at a higher range. These high prices can limit adoption by smaller labs and institution with limited budgets, which can be hard to justify for smaller labs and institutions with limited budgets. Furthermore, glycan analysis involves a multi-step sample preparation process, careful method development, and sophisticated data interpretation, which adds up to labor and training costs.

• For example, a single BlotGlyco Glycan Purification and Labeling Kit marketed by BIO, Vaupell Holdings Inc., was priced from USD 557.00 to USD 8,901.00. Such high prices can hinder adoption and adversely impact market growth.

Glycomics Market Opportunity

Technological Advancements in Spectrometry to Offer Growth Opportunities

A surge in technological advancements in spectrometry is creating a strong growth opportunity for the glycomics market. As demand for complex and faster glycan analysis increases, the market is expected to grow with technological advancements in spectrometry. These new generations of high-resolution mass spectrometers and automated sample-prep systems resolve subtle glycan structures, isomers, and site-specific glycosylation patterns that were previously difficult or too slow to measure. Such enhanced sensitivity and throughput facilitate the integration of glycan profiling in more quality control workflows. Many key companies are directing their resources toward technological advancements and new product launches for these spectrometers, underscoring the above advantages.  

• For instance, in June 2025, Agilent Technologies Inc. introduced its latest Hybrid Multisampler and highlighted innovations in the new LC Single Quadrupole Mass Spectrometers. These new additions are designed to boost laboratory efficiency and deliver superior results. Exhibition attendees will be able to see how these products can streamline operations and enhance analytical outcomes. An additional innovation in these spectrometry methods was the integration of a fluorescence detector, which requires minimal sample preparation for the most challenging UHPLC applications, including the analysis of glycans released from food and the detection of aflatoxins. Such developments are expected to boost growth.

Segmentation

Key Insights

The report covers the following key insights:

• New Product Launches
• Key Industry Developments
• Technological Advancements in Glycomics

Analysis by Product

Based on product, the market is subdivided into reagents & consumables, enzymes, kits, instruments, and services & software.

The reagents & consumables segment is expected to dominate the global glycomics market. A significant share is attributed to this segment, as glycomics workflows are consumables-intensive and have recurring costs. They have a high-margin demand that scales with the number of samples processed. Additionally, new product launches by key players specific to these workflows reinforce their dominance.

• For instance, in November 2021, GlycoPath Inc. launched the first research-based kit for N-glycan imaging mass spectrometry, providing researchers with the practical expertise and means to determine the tissue spatial distribution of N-glycans, thereby enhancing their biomedical investigations. Such developments are expected to propel the market growth.

Analysis by Application

Based on application, the market is fragmented into drug discovery & development, diagnostic and biomarker discovery, and others.

The drug discovery & development segment is estimated to dominate the market over the forecast period as glycomics is most deeply embedded in biologics and biosimilars pipelines. For various biologics and biosimilars such as monoclonal antibodies, fusion proteins, and advanced vaccines, glycosylation is a critical quality attribute that directly impacts efficacy, safety, and pharmacokinetics. Additionally, the drug discovery and development process operates on a large scale, resulting in an increased consumption of high-cost reagents and kits. Underscoring its high importance, many key companies are launching new products to cater to this increasing demand.

• For instance, in January 2023, SCIEX launched the Fast Glycan Labeling and Analysis kit for quantitative glycan analysis, along with an update for Biologics Explorer software to enhance critical protein therapeutic analysis workflows. The development expanded the company’s ability to support the characterization of complex and next-generation biopharmaceuticals across various stages of the drug development pipeline.

Analysis by End User

Based on the end-user, the market is subdivided into pharmaceutical & biotechnological companies, academic and research institutes, CROs& CDMOs, and others.

The pharmaceutical & biotechnology companies segment is anticipated to account for a dominant market share.  The dominance of the segment is attributed to extensive research and development spending for the production and research of numerous biologic vaccines and advanced therapies. These organizations also run large numbers of samples across multiple programs, generating substantial recurring revenue in the segment. Further, the increasing utilization for research purposes reinforces the dominance of pharmaceutical and biotechnology companies in the market.

• For instance, in June 2025, Idorsia Ltd. reached a milestone in the development of its first bacterial vaccine based on the company’s synthetic glycan chemistry platform. The Clostridioides difficile vaccine, based on a synthetic glycan mimicking a surface glycan antigen, demonstrated that the vaccine is well-tolerated and exhibits immunogenicity in a Phase 1 study. Such developments are expected to drive the segmental growth in the market.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, on the basis of region, has been analyzed across Europe, North America, Latin America, Asia Pacific, and the Middle East & Africa.

North America accounted for a 55.0% share of the global glycomics market. The region's dominance is attributed to a large base of biopharma companies working on monoclonal antibodies, biosimilars, advanced vaccines, and other biologics. There is also a mature ecosystem of CROs, CDMOs, and specialized analytics labs that offer glycan analysis as a service, increasing overall usage. Furthermore, the increasing development of drugs and the expansion of clinical trials in the region drive demand.  Together, these factors support the dominance of the regions for glycomics solutions. Such factors encourage strategic partnerships and collaborations among key players, driving regional growth.

• For instance, in December 2024, Palleon Pharmaceuticals collaborated with Shanghai Henlius Biotech, Inc. to develop and commercialize a human sialidase enzyme therapeutic, E-602, using Palleon’s glyco-immunology platform in combination with Henlius’ self-developed HANLIKANG in patients with autoimmune diseases, including lupus nephritis (LN).

The Europe market is expected to hold a substantial share of the global glycomics market. The market in the region is growing due to a strong network of academic centers and research institutes. The EU has funded several glycoscience and glycomics initiatives, promoting cross-border collaboration and accelerating the adoption of new technologies. Additionally, rising investments in innovative therapies and research in the region support significant market growth.

• For instance, in May 2025, Kyron.bio received a USD 6.0 million investment to utilize glycan engineering for advanced drug design. Such rising investments are expected to drive growth in the European region.

Asia Pacific is expected to grow at a significant CAGR and is one of the fastest-growing markets during the forecast period. The growth in the region is attributed to the expanding manufacturing capacity of emerging economies in the country, which increases the demand for glycomics to validate safety and efficiency. Additionally, the rising demand for healthcare and large patient populations are driving interest in new diagnostics and targeted therapies, where glycomics plays a critical role.

• For instance, in November 2025, GlycoNex, Inc. collaborated with Hokkaido University Hospital to support the development of its next-generation antibody-drug conjugate (ADC) GNX1021 in gastric cancer patients. Such developments are anticipated to boost growth in the region.

Key Players Covered

The global glycomics market is fragmented with the presence of a few groups and a large number of emerging companies.

The report includes the profiles of the following key players:

• Thermo Fisher Scientific (U.S.)
• Merck KGaA (Germany)
• Agilent Technologies (U.S.)
• Bruker Corporation (U.S.)
• Waters Corporation(U.S.)
• Shimadzu Corporation (Japan)
• New England Biolabs (U.S.)
• Takara Bio (Japan)
• Asparia Glycomics (Spain)

Key Industry Developments

• July 2022: Vector Laboratories launched its novel product, Glysite Scout Glycan Screening Kits. These immunofluorescence (IF) kits are fully integrated for the detection of glycan expression in tissue sections, enabling the profiling and characterization of complex glycans in biological systems.
• December 2020: Genovis launched new GlyCLICK kits for site-specific generation of custom ADCs carrying unique 2-step cleavable linker-payloads from Glykos Finland.